Sector News

Pharma company Allergan to invest €42m in Irish operations

March 2, 2017
Life sciences

Dublin-headquartered pharma company Allergan is to invest €42 million in its Irish operations this year.

The company, which employs approximately 1,700 people in the Republic, has also announced details of a new €50,000 innovation award programme with Irish colleges around the country.

In addition, the company said it will become the official sponsor of the Dubai Duty Free Irish Open hosted by the Rory Foundation as part of a three-year deal.

The announcements coincide with the Allergan global leadership team meeting in Dublin.

Allergan operates three facilities in Ireland. These include manufacturing operations at Clonshaugh, Dublin, and Westport, Co Mayo, as well as an international supply chain office in Earlsfort Terrace, Dublin.

The Westport and Clonshaugh facilities develop and manufacture a range of branded medicines primarily for the export market.

This year’s investment of €42 million across its Clonshaugh and Westport manufacturing operations will support increased manufacturing capabilities for some of Allergan’s key current and future products.

The investment in Westport will go towards adding additional capacity to its eye care manufacturing operations and the expansion of its ocular implant manufacturing facility.
Capacity increase

These moves are to accommodate both a capacity increase for existing products and the capability to accommodate new products using this technology platform, which are currently under development.

Speaking at the announcement, Taoiseach Enda Kenny said he had seen first-hand the impact the company has had in his native Mayo.

“Four decades ago, Allergan had the confidence and foresight to invest in Ireland, developing their first facility at Westport, Co Mayo, and a second facility in 1992 at Clonshaugh in north Dublin,” he said.

“I have seen first-hand the growth of the company in Mayo from roughly 25 jobs in 1977, and how they became an integral part of the community, which has since expanded to over 1,100 jobs in Westport.

“Allergan were amongst the early arrivals to Ireland and helped to sow the seeds of what was then our emerging pharmaceutical sector, which thankfully took root with much vigour over the intervening years.

“Allergan has undoubtedly made a significant contribution to making Ireland home to a world-class pharmaceutical industry and I wish to thank them for their ongoing commitment to their Irish operations.”

Allergan’s chief executive Brent Saunders said the Republic “continues to be a cornerstone” of the company’s growth.

“Our success has been built on strong teams globally, including our highly talented team we have here in Ireland, operating at state-of-the-art manufacturing facilities, producing pharmaceutical products for the global market,” he said.

“We are excited to announce continued investment in our Ireland operations, which will help Allergan continue to provide patients in Ireland and around the world with our innovative medicines.”

Allergan has commercial operations in approximately 100 countries, and employs more than 16,000 people worldwide.

The company has orchestrated a flurry of deals since its $160 billion merger with Pfizer collapsed in April.

By Colin Gleeson

Source: Irish Times

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend